BSE Live
Mar 23, 16:01Prev. Close
169.75
Open Price
168.85
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 23, 15:57Prev. Close
170.05
Open Price
168.21
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
160.20 (2347)
| Balance Sheet of Marksans Pharma (in Rs. Cr.) | Mar 10 | Mar 09 | Mar 08 | Mar 07 | Mar 06 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 36.78 | 36.78 | 35.94 | 35.94 | 35.94 | |
| Total Share Capital | 50.28 | 50.28 | 49.44 | 49.44 | 49.44 | |
| Reserves and Surplus | 125.37 | 108.82 | 92.04 | 77.12 | 70.00 | |
| Total Reserves and Surplus | 125.37 | 108.82 | 92.04 | 77.12 | 70.00 | |
| Total Shareholders Funds | 175.65 | 159.10 | 141.49 | 126.56 | 119.44 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 270.84 | 260.23 | 243.32 | 274.28 | 281.66 | |
| Deferred Tax Liabilities [Net] | 13.74 | 13.50 | 12.33 | 10.75 | 8.07 | |
| Other Long Term Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Provisions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Non-Current Liabilities | 284.57 | 273.74 | 255.65 | 285.03 | 289.74 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 82.06 | 58.83 | 59.79 | 44.44 | 20.93 | |
| Trade Payables | 35.24 | 36.58 | 45.87 | 44.22 | 32.53 | |
| Other Current Liabilities | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Short Term Provisions | 0.09 | 0.27 | 1.12 | 0.70 | 4.50 | |
| Total Current Liabilities | 117.39 | 95.69 | 106.79 | 89.36 | 57.97 | |
| Total Capital And Liabilities | 577.60 | 528.52 | 503.92 | 500.95 | 467.15 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 155.90 | 163.60 | 164.87 | 138.52 | 124.82 | |
| Intangible Assets | 138.24 | 115.36 | 40.19 | 0.00 | 0.00 | |
| Capital Work-In-Progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Fixed Assets | 294.14 | 278.96 | 205.06 | 138.52 | 124.82 | |
| Non-Current Investments | 77.62 | 67.56 | 2.70 | 2.69 | 0.26 | |
| Deferred Tax Assets [Net] | 2.24 | 2.26 | 2.32 | 2.25 | 2.38 | |
| Long Term Loans And Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Non-Current Assets | 0.21 | 0.48 | 1.08 | 1.90 | 1.86 | |
| Total Non-Current Assets | 374.20 | 349.25 | 211.16 | 145.36 | 129.32 | |
| CURRENT ASSETS | ||||||
| Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Inventories | 83.06 | 98.33 | 123.71 | 123.46 | 74.38 | |
| Trade Receivables | 67.20 | 50.82 | 52.85 | 53.34 | 46.41 | |
| Cash And Cash Equivalents | 32.51 | 13.01 | 43.20 | 158.45 | 197.30 | |
| Short Term Loans And Advances | 20.63 | 17.12 | 73.00 | 20.35 | 19.75 | |
| OtherCurrentAssets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Current Assets | 203.40 | 179.27 | 292.76 | 355.59 | 337.83 | |
| Total Assets | 577.60 | 528.52 | 503.92 | 500.95 | 467.15 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 23.43 | 0.86 | 0.00 | 0.00 | 0.07 | |
| CIF VALUE OF IMPORTS | ||||||
| Raw Materials | 15.22 | 20.65 | 28.73 | 35.61 | 27.32 | |
| Stores, Spares And Loose Tools | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Trade/Other Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capital Goods | 0.00 | 0.05 | 0.58 | 2.92 | 0.13 | |
| EXPENDITURE IN FOREIGN EXCHANGE | ||||||
| Expenditure In Foreign Currency | 1.29 | 0.60 | 0.30 | 0.11 | 0.15 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | ||||||
| Dividend Remittance In Foreign Currency | -- | -- | -- | -- | -- | |
| EARNINGS IN FOREIGN EXCHANGE | ||||||
| FOB Value Of Goods | 71.91 | 47.93 | 53.09 | 42.81 | 51.92 | |
| Other Earnings | -- | -- | -- | -- | -- | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | -- | -- | -- | -- | -- | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Non-Current Investments Unquoted Book Value | 77.62 | 67.56 | 2.70 | 2.69 | 0.26 | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Current Investments Unquoted Book Value | -- | -- | -- | -- | -- |
10.02.2026
Marksans Pharma Consolidated December 2025 Net Sales at Rs 754.43 crore, up 10.64% Y-o-Y
09.02.2026
Buy Marksans Pharma; target of Rs 225: Choice Institutional Equities
09.02.2026
Marksans Pharma Standalone December 2025 Net Sales at Rs 339.73 crore, up 8.93% Y-o-Y
26.11.2025
Marksans Pharma Consolidated September 2025 Net Sales at Rs 720.41 crore, up 12.23% Y-o-Y
10.02.2026
Marksans Pharma Consolidated December 2025 Net Sales at Rs 754.43 crore, up 10.64% Y-o-Y
09.02.2026
Marksans Pharma Standalone December 2025 Net Sales at Rs 339.73 crore, up 8.93% Y-o-Y
26.11.2025
Marksans Pharma Consolidated September 2025 Net Sales at Rs 720.41 crore, up 12.23% Y-o-Y
24.11.2025
Marksans Pharma Standalone September 2025 Net Sales at Rs 320.44 crore, up 3.83% Y-o-Y
23.03.2026
Alkem Laboratories gets DCGI nod for Semaglutide Injection; share price fall marginally
23.03.2026
22.03.2026
Sell-on-rise market? SBI Securities sees Nifty under pressure, picks two stocks for the week ahead
20.03.2026
Eris Lifesciences, Natco Pharma to launch generic Ozempic at 90% cheaper price
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth